DGAP-News

EVOTEC AND FORGE THERAPEUTICS FORM STRATEGIC 'SUPERBUG' ALLIANCE - Seite 2

hydroxamic acid) have yielded ineffective compounds that suffer from poor
drug-like properties. Thus, there are no approved therapeutics targeting
LpxC. Forge, using its innovative chemistry platform, has developed novel
non-hydroxamate inhibitors of LpxC that are safe and effective in an animal
model of Gram-negative infection and are able to kill Gram-negative
superbugs where other antibiotics are ineffective.

ABOUT FORGE THERAPEUTICS, INC.
Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that
leverages its novel chemistry platform to develop small molecule inhibitors
to target metalloproteins. Metalloproteins are proteins that require metal
ions for their biological function and make up over 1/3 of the proteins in
the human body. Forge uses a proprietary approach comprised of molecular
modelling for rational drug design along with fundamental knowledge and
expertise in bioinorganic chemistry to target metalloproteins. The name
Forge Therapeutics comes from two definitions for forge: to manipulate
(inhibit) a metal object (metalloprotein) and to move forward steadily with
a purpose (the Forge team). Forge Therapeutics, Inc., maintains its
headquarters in San Diego, California. To learn more please visit
www.ForgeTherapeutics.com.

Contact: [e-mail]

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer